Condition
Location

51 Cataract Trials

Power is an online platform that helps thousands of Cataract patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Image of trial facility.

K-321 Eye Drops for Fuchs' Dystrophy

Blue Ash, Ohio
This trial is testing K-321 to see if it helps people with FECD recover better after cataract surgery and descemetorhexis by supporting the healing of their cornea. K-321 has shown promise in treating corneal conditions like Fuchs' Endothelial Corneal Dystrophy (FECD).
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
110 Participants Needed
Image of trial facility.

New Lens for Cataracts

Cincinnati, Ohio
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
79 Participants Needed
Image of trial facility.

New Lens Implant for Cataract Surgery

Cincinnati, Ohio
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
79 Participants Needed
Image of trial facility.

Juvene IOL for Cataracts

Brecksville, Ohio
This trial is testing an artificial lens called Juvene® IOL for people who have had cataract surgery. The lens replaces the removed natural lens and helps improve overall vision, including seeing things up close.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
56 Participants Needed
Image of trial facility.

TECNIS® Intraocular Lens for Cataracts

Brecksville, Ohio
Prospective, multicenter, bilateral, interventional, controlled, masked (sponsor, subjects, and evaluators), randomized clinical trial.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
250 Participants Needed
Image of trial facility.

enVista EY Beyond Lens for Cataracts

Brecksville, Ohio
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
224 Participants Needed
Image of trial facility.

Intraocular Lenses for Cataracts

Brecksville, Ohio
A study to evaluate the real-world clinical performance of the enVista Aspire and Aspire Toric intraocular lens (IOL) models EA and ETA and to assess surgeon and subject satisfaction
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
450 Participants Needed
Image of trial facility.

AccuraSee™ Lens for Cataracts

Cleveland, Ohio
This is a study to evaluate the safety and effectiveness of the AccuraSee™ intraocular pseudophakic capsular lens (IOPCL) to improve near and/or intermediate vision following previous cataract surgery.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
10 Participants Needed
Image of trial facility.

SING-IMT for Late-Stage Age-Related Macular Degeneration

Cleveland, Ohio
This trial tests a tiny telescope implanted in the eye to help people with severe vision loss from late-stage AMD. The telescope magnifies images to improve vision by using healthy parts of the eye.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65+
Sex:All
125 Participants Needed
Image of trial facility.

MELT-300 for Sedation in Cataract Surgery

Hagerstown, Maryland
The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300. Researchers will compare MELT-300 to a placebo (a look-alike substance that contains no drug) to see if MELT-300 works on procedural sedation in adult participants undergoing CELR. Researchers will also include a comparator SL midazolam to confirm the benefit of inclusion of ketamine in the combined drug product. The main questions it aims to answer are: 1. Does MELT-300 is effective in comparison to placebo on procedural sedation for cataract surgery? 2. To determine the effectiveness of MELT-300 compared with midazolam on procedural sedation (to determine the contribution of ketamine component and inform the risk of ketamine in MELT-300) 3. To determine the time to achieve preoperative target sedation level with MELT-300 4. What medical problems do participants have when taking MELT-300 vs placebo Eligible participants will admitted to the study unit on Day 1. Participants will be randomized prior to surgery 4:1:1 to 1. MELT-300 (i.e. 1 MELT-300 sublingual tablet which contains 3 mg midazolam and 50 mg of ketamine) 2. Midazolam (i.e. 1 matching midazolam sublingual tablet which contains 3 mg midazolam) 3. Placebo (i.e. 1 matching placebo sublingual tablet) Participants will receive study medication 30 (± 5) minutes, without food or water, before planned surgery start (defined as instillation of topical ocular anesthetic gel \[i.e.. 3 drops of chloroprocaine hydrochloride ophthalmic gel)\]. The effectiveness of MELT-300 will be performed after study medication is administered before surgery, in the course of surgery, and postoperative on Day 1 (end of surgery defined as just prior to drape removal). The safety of MELT-300 will be performed at baseline, in the course of surgery, postoperatively on Day 1, and on Day 3 ± 1 day post dose of study medication.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
528 Participants Needed
Image of trial facility.

DEXYCU for Post-Surgical Inflammation in Childhood Cataract

Buffalo, New York
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:< 3
Sex:All
60 Participants Needed
Image of trial facility.

iDose TR + Cataract Surgery for Glaucoma

Kenosha, Wisconsin
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:45+
Sex:All
132 Participants Needed
Image of trial facility.

Combined Pre-operative Treatment for Cataracts

Racine, Wisconsin
This is a multicenter, 2-arm, randomized, prospective study of patients slated for bilateral cataract extraction. One eye will be randomized to the Study Arm, and the fellow eye will be randomized to the Control Arm.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
94 Participants Needed
Image of trial facility.

Phacoemulsification vs miCOR System for Cataract Surgery

Racine, Wisconsin
The purpose of this research study is to evaluate the clinical outcomes of current phacoemulsification approaches to cataract extraction involving high-frequency thermogenic energy versus the use of the MICOR System device using low-energy segment removal with a micro-interventional irrigation/aspiration port to evacuate the lens in subjects undergoing routine cataract surgery.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18+
Sex:All
375 Participants Needed
Image of trial facility.

Cabotegravir + Buprenorphine for Opioid Use Disorder

Durham, North Carolina
The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
300 Participants Needed
Image of trial facility.

Intraocular Lens Implants for Cataracts

Plymouth Meeting, Pennsylvania
Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study refined based on the Stage 1 data.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:40+
Sex:All
320 Participants Needed
Image of trial facility.

Balanced Salt Solution for Cataract Surgery

Town And Country, Missouri
This study aims to identify if the use of BSS PLUS® Sterile Intraocular Irrigating Solution as an irrigation solution leads to improved corneal outcomes vs BSS® Sterile Irrigating Solution in more compromised corneas.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:22+
Sex:All
27 Participants Needed
Image of trial facility.

IOL Implants for Vision Improvement

Liverpool, New York
This trial is studying the safety and performance of special artificial lenses used in cataract surgery. The study focuses on patients who have already received these lenses. These lenses help improve vision by replacing the eye's cloudy natural lens and focusing light correctly onto the retina.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
480 Participants Needed
Image of trial facility.

System-Level Intervention for Visual Impairment

New York, New York
Our team of community-based vision researchers has designed the Columbia University Multi-Level Intervention and Community-Engaged Research to Advance Vision Health (NEI-CER) to provide eye health screenings directly in Upper Manhattan communities, in familiar and accessible settings, to overcome multi-level social determinants of health (SDOH) which contribute to eye and vision health disparities. The proposed innovative, 2:1 cluster-randomized clinical trial, will recruit adults age 40 and older of diverse race/ethnicity (primarily African American and Hispanic/Latino) in Upper Manhattan with high rates of inadequate eye care. A total of 10 community health settings in Upper Manhattan, comprised of primary care offices, senior centers, and community organizations, confirms access to 17,000 individuals living at or below the NYC.gov poverty measure. This study will conduct ocular tests (visual acuity, intraocular pressure, fundus images) during screenings. To ensure that all participants receive the basic level of service, all participants who fail the eye health screening will be seen the same day by a study optometrist and eyeglasses will be provided at no charge. Educational workshops and a Community and Patient Advisory Board will support recruitment. System-Level Intervention Arm participants will receive ongoing support with scheduling eye exams and transportation by trained Community Engagement Coordinators. All participants will be followed prospectively for 2 years. The study is guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. An economic analysis will be conducted to evaluate the costs and benefits of the proposed multi-level Eye Health Screening Intervention. This will include calculating the cost per case of eye disease detected (such as glaucoma, cataracts, and retinal conditions) and assess the cost-effectiveness of the System-Level Intervention in comparison to Usual Care.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:40+
Sex:All
5840 Participants Needed
Image of trial facility.

Patient Navigator Intervention for Vision Impairment or Blindness

New York, New York
Dr. Lisa A. Hark (PI and Study Chair) and an interdisciplinary team have designed the New York City Eye Study (NYCES) to promote eye and vision health by conducting eye health screenings in adults age 21+ (PAR-23-009/NOT-EY-22-004).
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:21+
Sex:All
10000 Participants Needed
Image of trial facility.

Vision Screening + Patient Navigation for Eye Diseases

New York, New York
The investigators are conducting a 5-year prospective, 2:1 cluster-randomized controlled trial, funded by the Centers for Disease Control (CDC), which provides vision screenings to underserved New York City residents living in affordable housing buildings in Harlem and Washington Heights.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40+
Sex:All
749 Participants Needed
Image of trial facility.

AI-Based Screening for Glaucoma

Birmingham, Alabama
The goal of this clinical trial is to learn if implementation of an eye screening program at Federally Qualified Health Center (FQHC) clinics provides results that participants may have glaucoma, and/or other eye conditions (diabetic retinopathy, cataract, visual acuity impairment). The glaucoma screening will incorporate use of an artificial intelligence (AI)-assisted screening tool. This project is called AI-RONA. The main questions it aims to answer are: * How does this eye screening program compare to the rate of glaucoma and other eye conditions detected at other FQHC clinics where the screening program has not been implemented? * Do particpants who screen positive for these conditions adhere to the physician's recommendation for a follow-up examination by an optometrist or ophthalmologist? * Are referral rates for a follow-up comprehensive eye exam by an optometrist or ophthalmologist similar to those implemented by an ophthalmologist using telemedicine (that is, using the results of the screening to make a diagnosis remotely)? * What is the cost-effectiveness of the AI-assisted screening program in diagnosing glaucoma as compared to a physician-guided program? * Are participants completing the screening satisfied with it? * Are physicians at the FQHC clinics administering the screening satisfied with it? Participants will: * Undergo an ocular screening whose goal is to detect glaucoma, diabetic retinopathy, cataract, and/or impairment in visual acuity. If the screening indicates that participants may have these conditions, participants will be referred for a comprehensive eye examination by an optometrist or ophthalmologist. * Following the screening, participants and physicians will complete a survey on their satisfaction with the program.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
1800 Participants Needed
Image of trial facility.

Ketorolac for Cataracts

Westbury, New York
This is a clinical trial evaluating Ketorolac levels in vitreous and aqueous humor samples from patients undergoing combined cataract and pars plana vitrectomy surgeries with and without intracameral phenylephrine 1.0% / ketorolac 0.3% (OMIDRIA). Patients not receiving intracameral OMIDRIA will receive topical ketorolac prior to cataract surgery/pars plana vitrectomy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
20 Participants Needed
Image of trial facility.

Tecnis Symfony OptiBlue Lens for Cataracts

Greenwich, Connecticut
Tecnis Symfony Optiblue EDOF IOL is the latest version of Tecnis Symfony IOL with a violet light filter (VLF), which blocks short-wavelength light and improves the quality of vision while minimizing visual disturbances. The present study aims to assess the visual outcomes at distance, intermediate, and near following cataract surgery and implantation of Tecnis Symfony Optiblue IOL in patients with retinal comorbidities.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:50 - 85
Sex:All
15 Participants Needed
Image of trial facility.

Smartphone App Detection for Retinoblastoma

Memphis, Tennessee
This trial is testing a smartphone app called CRADLE to help detect leukocoria in children. The app takes pictures of the eyes and looks for signs of this condition. It aims to improve early detection in kids who have or might have serious eye diseases.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:< 7
Sex:All
290 Participants Needed
Image of trial facility.

Quatera 700 vs. Centurion for Cataract Surgery

Mount Pleasant, South Carolina
Phacoemulsification is the most common treatment for cataract surgery in the developed countries and over the years it gained importance due to several factors: small incision, surgery performed under topical anesthesia - which reduce injection-related complications - short recovery time, low post operatory induced astigmatism, and low incidence of surgical complications, when compared to the conventional surgeries. The study evaluates 2 different phacoemulsification devices in patients undergoing routine cataract surgery in both eyes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 80
Sex:All
40 Participants Needed
Image of trial facility.

Symfony vs Vivity Lenses for Cataracts

Mount Pleasant, South Carolina
The purpose of this study is to evaluate the visual outcomes of the Symfony lens and the Vivity lens under mesopic lighting conditions in adult patients undergoing routine cataract surgery. Participants will be asked to read a visual acuity chart at different distances in dim light.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:50+
Sex:All
64 Participants Needed
Image of trial facility.

Minimally Invasive Glaucoma Surgery + Cataract Surgery for Glaucoma

Fayetteville, Arkansas
This study is designed to determine how well patients with glaucoma can see following cataract surgery with a special type of lens called an extended-depth-of-focus (EDOF) lens. This lens is intended to reduced the patients need for glasses following cataract surgery. Patients will also undergo a minimally invasive type of glaucoma surgery using a special type of stent to reduce eye pressure, with the goal of better glaucoma control and the reduction in the need for medications to control eye pressure.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:45+
Sex:All
25 Participants Needed
Image of trial facility.

Clareon Vivity Toric IOL vs LAL+ for Cataracts

Bradenton, Florida
Phase 1 will be ambispective, multi-site, single arm study in age-related cataract patients with regular astigmatism, who were bilaterally treated with the LAL+ IOLs Phase 2 will be a prospective, randomized, unmasked, comparative, multi-site study with 90 days of follow up. Subjects will be randomized in a 1:1 manner to LAL+ or Clareon VIvity Toric IOLs.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:45+
Sex:All
250 Participants Needed
Image of trial facility.

AcrySof IQ Vivity IOL for Presbyopia

Fort Worth, Texas
The purpose of this post-market study is to describe the long-term safety and performance of AcrySof IQ Vivity and AcrySof IQ Vivity Toric intraocular lens (IOL) models in a real-world setting through routine clinical practice.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:22+
Sex:All
210 Participants Needed
Page 1 of 2+

Frequently Asked Questions

How much do Cataract clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Cataract clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Cataract trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Cataract is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Cataract medical study ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Cataract clinical trials ?

Most recently, we added System-Level Intervention for Visual Impairment, Cabotegravir + Buprenorphine for Opioid Use Disorder and Patient Navigator Intervention for Vision Impairment or Blindness to the Power online platform.

Other People Viewed

Imlifidase for Goodpasture Syndrome

RNA Disruption Assay for Breast Cancer

Scrambler Therapy for Neuropathic Pain

Interstitial Radiation Therapy for Kidney Cancer

Gene Therapy for Epilepsy

Cemiplimab + Ziv-Aflibercept for Uveal Melanoma

Botulinum Toxin for Raynaud's Disease

Ivosidenib for Blood Disorders

Evorpacept + Enfortumab Vedotin for Bladder Cancer

Methocarbamol + Opioids for Hernia Pain Management

Transcranial Direct Current Stimulation for Depression

Omega-3 Fatty Acids for Sickle Cell Disease

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top